血清P16自身抗体诊断乳腺良恶性病变患者的临床价值分析

Clinical Value of Serum P16 Autoantibody in the Diagnosis of Patients with Benign and Malignant Breast Lesions

目的探讨血清P16自身抗体诊断乳腺良恶性病变患者的临床价值。方法选取我院2015年6月至2017年11月收治的乳腺增生患者160例纳入良性组,乳腺癌患者170例纳入观察组,另抽取门诊健康者130例纳入对照组,将我院设计的P16表位多肽片段作为包被抗原,采用改良酶联免疫吸附试验(Elisa)检测三组血清中P16自身抗体的情况。结果良性组与对照组血清P16相近,差异比较无统计学意义(P>0.05),观察组血清P16高于良性组和对照组,差异比较有统计学意义(P<0.05);Ⅱ期、Ⅲ期乳腺癌患者血清P16均高于Ⅰ期乳腺癌患者,且Ⅱ期乳腺癌患者血清P16高于Ⅲ期乳腺癌患者,差异比较有统计学意义(P<0.05);P16在乳腺癌患者中检测的曲线下面积、敏感性、特异性均高于良性组患者,且Ⅱ期乳腺癌患者中的以上检测值均高于良性组与Ⅰ期、Ⅲ期乳腺癌组。结论血清P16自身抗体可反映乳腺良恶性病变过程,并作为其病变的血清学标志物。

Objective To explore the clinical value of serum P16 autoantibody in the diagnosis of patients with benign and malignant breast lesions. Methods A total of 160 patients with breast hyperplasia admitted to our hospital from June 2015 to November 2017 were enrolled in benign group, and 170 patients with breast cancer were included in observation group, and another 130 healthy peoplein outpatient department were included in control group. The P16 epitope polypeptide fragment designed by our hospital was used as a coating antigen, and the P16 autoantibody in serum was measured in the three groups by modified enzyme-linked immunosorbent assay(Elisa). Results The serum P16 was similar in benign group and control group(P>0.05), and the serum P16 in observation group was higher than that in benign group and control group(P<0.05). The serum P16 of patients with stage Ⅱ and stage Ⅲ breast cancer was higher than that ofpatients with stage Ⅰ breast cancer, and the serum P16 of patients with stage Ⅱ breast cancer was higher than that of patients with stage Ⅲ breast cancer(P<0.05).The area under the curve, sensitivity and specificity of P16 in the detection of breast cancer patientswere higher than those in benign group, and the above values in patients with stage Ⅱ breast cancer were higher than those in benign group and stage Ⅰ and stage Ⅲ breast cancer groups. Conclusion Serum P16 autoantibody can reflect the process of benign and malignant breast, and it can serve as serological marker of lesions.